Literature DB >> 29497579

Cognitive Impairment Associated with Cancer: A Brief Review.

J Cara Pendergrass1,2, Steven D Targum1,2, John E Harrison1,2.   

Abstract

This brief review explores the areas of cognitive impairment that have been observed in cancer patients and survivors, the cognitive assessment tools used, and the management of the observed cognitive changes. Cognitive changes and impairment observed in patients with cancer and those in remission can be related to the direct effects of cancer itself, nonspecific factors or comorbid conditions that are independent of the actual disease, and/or the treatments or combination of treatments administered. Attention, memory, and executive functioning are the most frequently identified cognitive domains impacted by cancer. However, the prevalence and extent of impairment remains largely unknown due to marked differences in methodology, definitions of cognitive impairment, and the assessment measures used. Assessment of cognitive functioning is an important and necessary part of a comprehensive oncological care plan. Research is needed to establish a better understanding of cognitive changes and impairments associated with cancer so that optimal patient outcomes can be achieved.

Entities:  

Keywords:  Cognition; cancer; chemotherapy; cognitive impairment; neuropsychological assessment; treatment

Year:  2018        PMID: 29497579      PMCID: PMC5819720     

Source DB:  PubMed          Journal:  Innov Clin Neurosci        ISSN: 2158-8333


  105 in total

1.  Alterations in brain activation during working memory processing associated with breast cancer and treatment: a prospective functional magnetic resonance imaging study.

Authors:  Brenna C McDonald; Susan K Conroy; Tim A Ahles; John D West; Andrew J Saykin
Journal:  J Clin Oncol       Date:  2012-06-04       Impact factor: 44.544

2.  Non-protein bound iron release during chemotherapy in cancer patients.

Authors:  N I Weijl; T J Elsendoorn; R M W Moison; E G W M Lentjes; R Brand; H M Berger; S Osanto
Journal:  Clin Sci (Lond)       Date:  2004-05       Impact factor: 6.124

Review 3.  Candidate mechanisms for chemotherapy-induced cognitive changes.

Authors:  Tim A Ahles; Andrew J Saykin
Journal:  Nat Rev Cancer       Date:  2007-03       Impact factor: 60.716

4.  Regional brain activation during verbal declarative memory in metastatic breast cancer.

Authors:  Shelli R Kesler; F Chris Bennett; Misty L Mahaffey; David Spiegel
Journal:  Clin Cancer Res       Date:  2009-10-20       Impact factor: 12.531

Review 5.  Systematic review of pharmacologic and non-pharmacologic interventions to manage cognitive alterations after chemotherapy for breast cancer.

Authors:  Raymond J Chan; Alexandra L McCarthy; Jackie Devenish; Karen A Sullivan; Alexandre Chan
Journal:  Eur J Cancer       Date:  2015-01-23       Impact factor: 9.162

6.  A randomized trial on the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary brain tumor.

Authors:  K Gehring; S Y Patwardhan; R Collins; M D Groves; C J Etzel; C A Meyers; J S Wefel
Journal:  J Neurooncol       Date:  2011-10-02       Impact factor: 4.130

7.  Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome.

Authors:  Christina A Meyers; Maher Albitar; Elihu Estey
Journal:  Cancer       Date:  2005-08-15       Impact factor: 6.860

8.  Comparing neuropsychological tasks to optimize brief cognitive batteries for brain tumor clinical trials.

Authors:  Sarah K Lageman; Jane H Cerhan; Dona E C Locke; S Keith Anderson; Wenting Wu; Paul D Brown
Journal:  J Neurooncol       Date:  2009-07-19       Impact factor: 4.130

Review 9.  Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management.

Authors:  Carla C P Verstappen; Jan J Heimans; Klaas Hoekman; Tjeerd J Postma
Journal:  Drugs       Date:  2003       Impact factor: 9.546

10.  Confronting chemobrain: an in-depth look at survivors' reports of impact on work, social networks, and health care response.

Authors:  Nelli Boykoff; Mona Moieni; Saskia Karen Subramanian
Journal:  J Cancer Surviv       Date:  2009-09-16       Impact factor: 4.442

View more
  54 in total

1.  Correlates of cognitive impairment in adult cancer survivors who have received chemotherapy and report cognitive problems.

Authors:  Shannon L Gutenkunst; Janette L Vardy; Haryana M Dhillon; Melanie L Bell
Journal:  Support Care Cancer       Date:  2020-07-14       Impact factor: 3.603

2.  Long-term clinically relevant rodent model of methotrexate-induced cognitive impairment.

Authors:  Connor Berlin; Katharine Lange; H Carl Lekaye; Kelsey Hopland; Samantha Phillips; Jinghua Piao; Viviane Tabar
Journal:  Neuro Oncol       Date:  2020-08-17       Impact factor: 12.300

3.  The role of depression in the relationship between cognitive decline and quality of life among breast cancer patients.

Authors:  Jin-Hee Park; Yong Sik Jung; Young-Mi Jung; Sun Hyoung Bae
Journal:  Support Care Cancer       Date:  2018-11-29       Impact factor: 3.603

4.  Cognitive functioning following brain irradiation as part of cancer treatment: Characterizing better cognitive performance.

Authors:  Shan S Wong; L Douglas Case; Nancy E Avis; Tiffany L Cummings; Christina K Cramer; Stephen R Rapp
Journal:  Psychooncology       Date:  2019-08-30       Impact factor: 3.894

5.  Age-dependent brain volume and neuropsychological changes after chemotherapy in breast cancer patients.

Authors:  Jeroen Blommaert; Gwen Schroyen; Mathieu Vandenbulcke; Ahmed Radwan; Ann Smeets; Ron Peeters; Charlotte Sleurs; Patrick Neven; Hans Wildiers; Frédéric Amant; Stefan Sunaert; Sabine Deprez
Journal:  Hum Brain Mapp       Date:  2019-08-21       Impact factor: 5.038

6.  Predictors of financial toxicity and its associations with health-related quality of life and treatment non-adherence in Turkish cancer patients.

Authors:  Duygu Ürek; Özgür Uğurluoğlu
Journal:  Support Care Cancer       Date:  2021-08-15       Impact factor: 3.603

7.  Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia.

Authors:  Kerry A Rogers; Ying Huang; Amy S Ruppert; Lynne V Abruzzo; Barbara L Andersen; Farrukh T Awan; Seema A Bhat; Allison Dean; Margaret Lucas; Christin Banks; Cara Grantier; Nyla A Heerema; Gerard Lozanski; Kami J Maddocks; Thomas R Valentine; David M Weiss; Jeffrey A Jones; Jennifer A Woyach; John C Byrd
Journal:  J Clin Oncol       Date:  2020-08-14       Impact factor: 44.544

8.  Changes in Attentional Function in Patients From Before Through 12 Months After Breast Cancer Surgery.

Authors:  Carmen Kohler; Ming Chang; Yu-Yin Allemann-Su; Marcus Vetter; Miyeon Jung; Misook Jung; Yvette Conley; Steven Paul; Kord M Kober; Bruce A Cooper; Betty Smoot; Jon D Levine; Christine Miaskowski; Maria C Katapodi
Journal:  J Pain Symptom Manage       Date:  2020-01-15       Impact factor: 3.612

9.  Risk of cognition alteration and emotional frailty via circulating transcriptome in treatment naïve head and neck squamous cell cancer patients.

Authors:  A M Anusa; Rooban Thavarajah
Journal:  J Oral Biol Craniofac Res       Date:  2019-03-13

Review 10.  Cancer-related cognitive impairment in patients with non-central nervous system malignancies: an overview for oncology providers from the MASCC Neurological Complications Study Group.

Authors:  Samantha J Mayo; Maryam Lustberg; Haryana M Dhillon; Zev M Nakamura; Deborah H Allen; Diane Von Ah; Michelle C Janelsins; Alexandre Chan; Karin Olson; Chia Jie Tan; Yi Long Toh; Jeong Oh; Lisa Grech; Yin Ting Cheung; Ishwaria Mohan Subbiah; Duska Petranovic; James D'Olimpio; Margherita Gobbo; Susanne Koeppen; Charles L Loprinzi; Linda Pang; Shivani Shinde; Olanipekun Ntukidem; Katherine B Peters
Journal:  Support Care Cancer       Date:  2020-11-24       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.